Dexamethasone Treatment Options

A collection of 1465 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.

Home

All Treatments

Dexamethasone

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

NCT02252172

Completed

The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Not set, Birmingham, Alabama +209 locations

Not set, Birmingham, Alabama

Not set, Mobile, Alabama

Not set, Glendale, Arizona

Not set, Berkeley, California

Not set, Beverly Hills, California

Not set, El Cajon, California

Not set, Greenbrae, California

Not set, Los Angeles, California

Not set, Oceanside, California

Not set, San Diego, California

Not set, West Hills, California

Not set, Whittier, California

Not set, Denver, Colorado

Not set, Fort Collins, Colorado

Not set, Glenwood Springs, Colorado

Not set, New Haven, Connecticut

Not set, Norwalk, Connecticut

Not set, Washington, District of Columbia

Not set, Boca Raton, Florida

Not set, Boynton Beach, Florida

Not set, Fort Lauderdale, Florida

Not set, Fort Myers, Florida

Not set, Hollywood, Florida

Not set, Jacksonville, Florida

Not set, Lake City, Florida

Not set, Saint Petersburg, Florida

Not set, Weston, Florida

Not set, Atlanta, Georgia

Not set, Augusta, Georgia

Not set, Macon, Georgia

Not set, Marietta, Georgia

Not set, Chicago, Illinois

Not set, Niles, Illinois

Not set, Fort Wayne, Indiana

Not set, Iowa City, Iowa

Not set, Louisville, Kentucky

Not set, Lafayette, Louisiana

Not set, Marrero, Louisiana

Not set, Shreveport, Louisiana

Not set, Annapolis, Maryland

Not set, Baltimore, Maryland

Not set, Frederick, Maryland

Not set, Boston, Massachusetts

Not set, Detroit, Michigan

Not set, Duluth, Minnesota

Not set, Rochester, Minnesota

Not set, Kansas City, Missouri

Not set, Saint Louis, Missouri

Not set, Omaha, Nebraska

Not set, Hooksett, New Hampshire

Not set, Brick, New Jersey

Not set, Hackensack, New Jersey

Not set, Livingston, New Jersey

Not set, Plainfield, New Jersey

Not set, Summit, New Jersey

Not set, Mineola, New York

Not set, New York, New York

Not set, Rochester, New York

Not set, Asheboro, North Carolina

Not set, Charlotte, North Carolina

Not set, Pinehurst, North Carolina

Not set, Winston-Salem, North Carolina

Not set, Canton, Ohio

Not set, Cleveland, Ohio

Not set, Columbus, Ohio

Not set, Bend, Oregon

Not set, Bethlehem, Pennsylvania

Not set, Pittsburgh, Pennsylvania

Not set, Spartanburg, South Carolina

Not set, Sioux Falls, South Dakota

Not set, Chattanooga, Tennessee

Not set, Nashville, Tennessee

Not set, Arlington, Texas

Not set, Edinburg, Texas

Not set, Fort Sam Houston, Texas

Not set, Fort Worth, Texas

Not set, Houston, Texas

Not set, Plano, Texas

Not set, San Antonio, Texas

Not set, Ogden, Utah

Not set, Seattle, Washington

Not set, Spokane, Washington

Not set, Tacoma, Washington

Not set, Box Hill, Not set

Not set, Fitzroy, Not set

Not set, Footscray, Not set

Not set, Kogarah, Not set

Not set, Kurralta Park, Not set

Not set, Nedlands, Not set

Not set, New South Wales, Not set

Not set, Woodville, Not set

Not set, Woolloongabba N/a, Not set

Not set, Innsbruck, Not set

Not set, Linz, Not set

Not set, Salzburg, Not set

Not set, Wien N/a, Not set

Not set, Wien Wien, Not set

Not set, Brugge, Not set

Not set, Brussels, Not set

Not set, Brussel, Not set

Not set, Haine Saint Paul La Louviere, Not set

Not set, Leuven, Not set

Not set, Liege, Not set

Not set, Calgary, Alberta

Not set, Toronto, Ontario

Not set, Greenfield Park, Quebec

Not set, Montreal, Quebec

Not set, Montréal, Quebec

Not set, N/a N/a, Not set

Not set, Nova Scotia, Not set

Not set, Quebec, Not set

Not set, Aarhus C, Not set

Not set, Odense, Not set

Not set, Vejle, Not set

Not set, Amiens N/a Picardie, Not set

Not set, Angers, Not set

Not set, Bayonne Cedex, Not set

Not set, Bretagne, Not set

Not set, Caen, Not set

Not set, Cergy Pontoise, Not set

Not set, Chalons Sur Saone, Not set

Not set, Clermont-Ferrand, Not set

Not set, Creteil, Not set

Not set, Dijon, Not set

Not set, Dunkerque Cedex 1, Not set

Not set, Grenoble Cedex 9, Not set

Not set, La Roche sur Yon Cedex 9, Not set

Not set, Le Chesnay Cedex, Not set

Not set, Le Mans, Not set

Not set, Lille Cedex, Not set

Not set, Lille, Not set

Not set, Limoges, Not set

Not set, Lyon, Not set

Not set, Marseille Cedex 9, Not set

Not set, Metz-Tessy, Not set

Not set, Montivilliers, Not set

Not set, Montpellier, Not set

Not set, Mulhouse, Not set

Not set, Nantes, Not set

Not set, Nice N/a, Not set

Not set, Paris Cedex 12, Not set

Not set, Paris, Not set

Not set, PERIGUEUX cedex, Not set

Not set, Perpignan, Not set

Not set, Pessac, Not set

Not set, Poitiers, Not set

Not set, Reims, Not set

Not set, Rennes, Not set

Not set, Rouen Cedex, Not set

Not set, Saint Brieuc Cedex 1, Not set

Not set, Saint Priest en Jarez, Not set

Not set, St Malo Cedex, Not set

Not set, St Quentin Cedex, Not set

Not set, Strasbourg, Not set

Not set, Toulouse Cedex 9, Not set

Not set, TOURS Cedex 9, Not set

Not set, Vandoeuvre Les Nancy, Not set

Not set, Aschaffenburg, Not set

Not set, Bad Berka, Not set

Not set, Bonn, Not set

Not set, Braunschweig, Not set

Not set, Dresden, Not set

Not set, Essen, Not set

Not set, Frankfurt, Not set

Not set, Hannover, Not set

Not set, Heidelberg, Not set

Not set, Hessen, Not set

Not set, Kiel, Not set

Not set, Koblenz, Not set

Not set, Mainz, Not set

Not set, Mannheim, Not set

Not set, Rostock, Not set

Not set, Schwerin, Not set

Not set, Stuttgart, Not set

Not set, Tuebingen, Not set

Not set, Ulm, Not set

Not set, Villingen-Schwenningen, Not set

Not set, Dublin, Not set

Not set, Galway, Not set

Not set, Hadera, Not set

Not set, Haifa, Not set

Not set, Jerusalem, Not set

Not set, Nahariya, Not set

Not set, Petah Tikva, Not set

Not set, Tel-Aviv, Not set

Not set, Hilversum, Not set

Not set, Hoofddorp, Not set

Not set, Rotterdam, Not set

Not set, Tilburg, Not set

Not set, Falun, Not set

Not set, Göteborg, Not set

Not set, Halmstad, Not set

Not set, Helsingborg, Not set

Not set, Huddinge, Not set

Not set, Lulea, Not set

Not set, Lund, Not set

Not set, Stockholm, Not set

Not set, Örebro, Not set

Not set, Aberdeen, Not set

Not set, Canterbury, Not set

Not set, Dundee, Not set

Not set, Leeds, Not set

Not set, London, Not set

Not set, Manchester, Not set

Not set, Nottingham, Not set

Not set, Oxford, Not set

Not set, Plymouth, Not set

Not set, Southampton, Not set

Not set, Truro, Not set

Not set, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

NCT05192889

Active Not Recruiting

This is a phase I/II clinical trial evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with relapsed or refractory acute lymphoblastic leukemia or lymphoma (rALL) and assessing the combination dose of venetoclax combinations with either blinatumomab for CD19-postive patients or navitoclax and high-dose cytarabine for CD19-negative patients. Primary Objectives * To compare Minimal Residual Disease (MRD)-negative CR/CRi rate in children with relapsed o... Read More

Gender:

ALL

Ages:

Between 4 years and 30 years

Trial Updated:

05/23/2025

Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations

Conditions: Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia

Learn More ›

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825

Active Not Recruiting

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: Research Site, Duarte, California +89 locations

Research Site, Duarte, California

Research Site, Palo Alto, California

Research Site, San Francisco, California

Research Site, Weston, Florida

Research Site, Indianapolis, Indiana

Research Site, New Orleans, Louisiana

Research Site, Boston, Massachusetts

Research Site, Detroit, Michigan

Research Site, Rochester, Minnesota

Research Site, Saint Louis, Missouri

Research Site, New York, New York

Research Site, Rochester, New York

Research Site, Winston-Salem, North Carolina

Research Site, Cleveland, Ohio

Research Site, Columbus, Ohio

Research Site, Portland, Oregon

Research Site, Philadelphia, Pennsylvania

Research Site, Nashville, Tennessee

Research Site, Dallas, Texas

Research Site, Houston, Texas

Research Site, Salt Lake City, Utah

Research Site, Seattle, Washington

Research Site, Milwaukee, Wisconsin

Research Site, Box Hill, Not set

Research Site, Brisbane, Not set

Research Site, Westmead, Not set

Research Site, Linz, Not set

Research Site, Vienna, Not set

Research Site, Anderlecht, Not set

Research Site, Leuven, Not set

Research Site, Porto Alegre, Not set

Research Site, Ribeirão Preto, Not set

Research Site, S.J. Do Rio Preto, Not set

Research Site, Salvador, Not set

Research Site, Calgary, Alberta

Research Site, Edmonton, Alberta

Research Site, Toronto, Ontario

Research Site, Beijing, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Wenzhou, Not set

Research Site, Wuhan, Not set

Research Site, Ostrava - Poruba, Not set

Research Site, Prague, Not set

Research Site, Caen, Not set

Research Site, Creteil, Not set

Research Site, Limoges, Not set

Research Site, Marseille, Not set

Research Site, Paris, Not set

Research Site, Pessac, Not set

Research Site, Pierre-Benite, Not set

Research Site, Poitiers, Not set

Research Site, Rennes, Not set

Research Site, Toulouse, Not set

Research Site, Tours, Not set

Research Site, Berlin, Not set

Research Site, Duesseldorf, Not set

Research Site, Essen, Not set

Research Site, Hamburg, Not set

Research Site, Heidelberg, Not set

Research Site, Wuerzburg, Not set

Research Site, Athens, Not set

Research Site, Rio, Not set

Research Site, Haifa, Not set

Research Site, Jerusalem, Not set

Research Site, Tel Hashomer, Not set

Research Site, Napoli, Not set

Research Site, Pavia, Not set

Research Site, Pisa, Not set

Research Site, Roma, Not set

Research Site, Fukushima-shi, Not set

Research Site, Nagoya-shi, Not set

Research Site, Shibuya-ku, Not set

Research Site, Seoul, Not set

Research Site, Groningen, Not set

Research Site, Utrecht, Not set

Research Site, Gdańsk, Not set

Research Site, Poznan, Not set

Research Site, Warszawa, Not set

Research Site, Barcelona, Not set

Research Site, Gijón, Not set

Research Site, Majadahonda, Not set

Research Site, Pamplona, Not set

Research Site, Sevilla, Not set

Research Site, London, Not set

Conditions: AL Amyloidosis

Learn More ›

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

NCT03201965

Completed

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: Mayo Clinic Arizona, Phoenix, Arizona +139 locations

Mayo Clinic Arizona, Phoenix, Arizona

City of Hope, Duarte, California

University of California San Francisco, San Francisco, California

Stanford University, Stanford, California

University of Colorado, Aurora, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Mayo Clinic, Jacksonville, Florida

Winship Cancer Institute Emory University, Atlanta, Georgia

University of Maryland, Baltimore, Maryland

Tufts Medical Center, Boston, Massachusetts

Boston University Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Washington University School Of Medicine, Saint Louis, Missouri

Columbia University Medical Center, New York, New York

Weill Cornell Medical College, New York, New York

University of Rochester Medical Center, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Wake Forest University Health Sciences - Cardiovascular Medicine, Winston-Salem, North Carolina

Cleveland Clinic, Cleveland, Ohio

The Ohio State University, Columbus, Ohio

Oregon Health And Science University, Portland, Oregon

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

University of Texas, MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Seattle Cancer Care Alliance, Seattle, Washington

Box Hill Hospital, Box Hill, Not set

Sir Charles Gairdner Hospital, Nedlands, Not set

Westmead Hospital, Westmead, Not set

Princess Alexandra Hospital, Woolloongabba, Not set

Institut Jules Bordet, Anderlecht, Not set

UZ Gent, Gent, Not set

Az Groeninge, Kortrijk, Not set

Universitair Ziekenhuis Leuven, Leuven, Not set

Hospital das Clinicas de Porto Alegre, Porto Alegre, Not set

Sociedade Pernambucana de Combate ao Cancer, Recife, Not set

Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, Not set

Hospital Sao Rafael, Salvador, Not set

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, Sao Jose do Rio Preto, Not set

Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE, Sao Paulo, Not set

Clinica Sao Germano, São Paulo, Not set

Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Not set

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta

Alberta Health Services, Edmonton, Alberta

Vancouver General Hospital, Vancouver, British Columbia

London Health Sciences Center, London, Ontario

University Health Network UHN Princess Margaret Cancer Centre, Toronto, Ontario

McGill University Health Centre, Montreal, Quebec

Peking University First Hospital, Beijing, Not set

Peking University People s Hospital, Beijing, Not set

First affiliated Hospital of Zhejiang University, Hangzhou, Not set

Ruijin Hospital Shanghai Jiao Tong University, Shanghai, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

Aarhus University Hospital, Aarhus N, Not set

Dep. of Hematology, Rigshospitalet, Copenhagen, Not set

Odense Universitets Hospital, Odense, Not set

CHU Dijon, Dijon, Not set

Hopital Claude Huriez, Lille cedex, Not set

CHU de Limoges - Fédération Hépatologie, Limoges, Not set

Institut Paoli Calmettes, Marseille, Not set

Chu Hotel Dieu, Nantes cedex 01, Not set

Hopital Saint Louis, PARIS cedex 10, Not set

Centre hospitalier Lyon-Sud, Pierre - Bénite cedex, Not set

CHU De Poitiers, Poitiers, Not set

CHU Rangueil, Toulouse, Not set

CHU Bretonneau, Tours cedex, Not set

CHU de Nancy_ Hopital Brabois, Vandoeuvre les Nancy, Not set

Charite Campus Benjamin Franklin, Berlin, Not set

Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Not set

Universitatsklinikum Essen, Essen, Not set

HOPA-Hämatologisch-Onkologische Praxis Altona MVZ GmbH, Hamburg, Not set

Universitaetsklinikum Heidelberg Medizinische Klinik V, Heidelberg, Not set

Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,, Tübingen, Not set

Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii, Würzburg, Not set

Alexandra General Hospital of Athens, Athens, Not set

University General Hospital of Rio, Patra, Not set

Semmelweis Egyetem I.Belgyogyaszati Klinika, Budapest, Not set

Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely, Budapest, Not set

Carmel Hospital, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Sheba Medical Center, Ramat-Gan, Not set

Sourasky Medical Center, Tel-Aviv, Not set

Assaf Ha'Rofeh Medical Center, Zerifin, Not set

Policlinico di Bari, Bari, Not set

Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi, Bologna, Not set

Casa di Cura La Maddalena, Palermo, Not set

Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Dipartimento Di Biotecnologie Cellulari Ed Ematologia-Università ''La Sapienza'',Policlinico Umberto I, Roma, Not set

A.O.U. Città della Salute e della Scienza, Torino, Not set

Fukushima Medical University Hospital, Fukushima, Not set

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Not set

Teine Keijinkai Hospital, Hokkaido, Not set

Kanazawa University Hospital, Kanazawa, Not set

Kumamoto University Hospital, Kumamoto-City, Not set

Kyoto Kuramaguchi Medical Center, Kyoto, Not set

Shinshu University Hospital, Matsumoto, Not set

Matsuyama Red Cross Hospital, Matsuyama, Not set

Nagoya City University Hospital, Nagoya, Not set

National Hospital Organization Okayama Medical Center, Okayama, Not set

Japanese Red Cross Medical Center, Shibuya, Not set

Tokushima University Hospital, Tokushima, Not set

Pusan National University Hospital, Busan, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Centro de Investigación Farmacéutica Especializada, Guadalajara, Not set

Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Not set

Haga ziekenhuis, Den Haag, Not set

UMCG, Groningen, Not set

Erasmus MC, Rotterdam, Not set

UMC Utrecht, Utrecht, Not set

Maxima Medisch Centrum, Veldhoven, Not set

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set

SKPP UM w Poznaniu, Poznan, Not set

Instytut Hematologii i Transfuzjologii, Warszawa, Not set

Inst. Cat. D'Oncologia-Badalona, Badalona, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp Clinic de Barcelona, Barcelona, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp Univ Fund Jimenez Diaz, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Hosp Clinico Univ de Salamanca, Salamanca, Not set

Hosp. Univ. de Canarias, San Cristóbal de La Laguna, Not set

Hosp. Univ. Dr. Peset, Valencia, Not set

South Elvsborg Hospital, Boras, Not set

Skanes universitetssjukhus, Lund, Not set

Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Not set

Akdeniz University Medical Faculty, Antalya, Not set

Ondokuz Mayis Universitesi Tip Fakultesiy, Atakum, Not set

Istanbul University Istanbul Medical Faculty, Istanbul, Not set

Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set

Erciyes University Medical Faculty, Talas, Not set

University Hospitals Birmingham NHS Trust,, Birmingham, Not set

University College Hospital, London, Not set

Conditions: Amyloidosis

Learn More ›

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235

Active Not Recruiting

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: Research Site, Scottsdale, Arizona +109 locations

Research Site, Scottsdale, Arizona

Research Site, Duarte, California

Research Site, Palo Alto, California

Research Site, San Francisco, California

Research Site, Jacksonville, Florida

Research Site, Weston, Florida

Research Site, Indianapolis, Indiana

Research Site, New Orleans, Louisiana

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Detroit, Michigan

Research Site, Rochester, Minnesota

Research Site, Saint Louis, Missouri

Research Site, New York, New York

Research Site, Rochester, New York

Research Site, Chapel Hill, North Carolina

Research Site, Durham, North Carolina

Research Site, Winston-Salem, North Carolina

Research Site, Cleveland, Ohio

Research Site, Columbus, Ohio

Research Site, Portland, Oregon

Research Site, Philadelphia, Pennsylvania

Research Site, Nashville, Tennessee

Research Site, Dallas, Texas

Research Site, Houston, Texas

Research Site, Salt Lake City, Utah

Research Site, Seattle, Washington

Research Site, Madison, Wisconsin

Research Site, Milwaukee, Wisconsin

Research Site, Box Hill, Not set

Research Site, Murdoch, Not set

Research Site, Westmead, Not set

Research Site, Woolloongabba, Not set

Research Site, Linz, Not set

Research Site, Vienna, Not set

Research Site, Anderlecht, Not set

Research Site, Leuven, Not set

Research Site, Porto Alegre, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Salvador, Not set

Research Site, Calgary, Alberta

Research Site, Toronto, Ontario

Research Site, Beijing, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Shanghai, Not set

Research Site, Suzhou, Not set

Research Site, Wenzhou, Not set

Research Site, Wuhan, Not set

Research Site, Ostrava Poruba, Not set

Research Site, Prague, Not set

Research Site, Caen, Not set

Research Site, Creteil, Not set

Research Site, Dijon, Not set

Research Site, Lille, Not set

Research Site, Limoges, Not set

Research Site, Marseille, Not set

Research Site, Paris, Not set

Research Site, Pessac, Not set

Research Site, Pierre Benite, Not set

Research Site, Poitiers, Not set

Research Site, Rennes, Not set

Research Site, Toulouse, Not set

Research Site, Tours, Not set

Research Site, Berlin, Not set

Research Site, Düsseldorf, Not set

Research Site, Essen, Not set

Research Site, Hamburg, Not set

Research Site, Heidelberg, Not set

Research Site, Wuerzburg, Not set

Research Site, Athens, Not set

Research Site, Rio, Not set

Research Site, Thessaloniki, Not set

Research Site, Haifa, Not set

Research Site, Jerusalem, Not set

Research Site, Petah Tikva, Not set

Research Site, Tel Aviv, Not set

Research Site, Tel Hashomer, Not set

Research Site, Brescia, Not set

Research Site, Fukushima-shi, Not set

Research Site, Kanazawa-shi, Not set

Research Site, Kashiwa-shi, Not set

Research Site, Kita-ku, Not set

Research Site, Kumamoto-shi, Not set

Research Site, Matsumoto-shi, Not set

Research Site, Nagoya-shi, Not set

Research Site, Shibuya-ku, Not set

Research Site, Seoul, Not set

Research Site, Gdańsk, Not set

Research Site, Warszawa, Not set

Research Site, St. Petersburg, Not set

Research Site, Barcelona, Not set

Research Site, Gijón, Not set

Research Site, Granada, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Pamplona, Not set

Research Site, Salamanca, Not set

Research Site, Sevilla, Not set

Research Site, Valencia, Not set

Research Site, Glasgow, Not set

Research Site, London, Not set

Conditions: AL Amyloidosis

Learn More ›

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866

Active Not Recruiting

The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: Compassionate Cancer Care, Fountain Valley, California +35 locations

Compassionate Cancer Care, Fountain Valley, California

Virginia Cancer Specialists, Fairfax, Virginia

UW Medicine Valley Medical Center, Renton, Washington

CHU Brest, Brest, Not set

Centre Leon Berard, Lyon Cedex 8, Not set

Hopital Cochin, Paris, Not set

Hopital Europeen Georges-Pompidou, Paris, Not set

CHU Rouen Hopital Charles Nicolle, Rouen, Not set

Nouvel Hopital Civil - CHU Strasbourg, Strasbourg CEDEX, Not set

Chungbuk National University Hospital, Cheongju-si, Not set

National Cancer Center, Gyeonggi-do, Not set

Gachon University Gil Medical Center, Incheon, Not set

Chonnam National University Hwasun Hospital, Jeollanam-do, Not set

Seoul National University Bundang Hospital, Seongnam si, Not set

Asan Medical Center, Seoul, Not set

Hosp. de La Santa Creu I Sant Pau, Barcelona, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp. Univ. Quiron Dexeus, Barcelona, Not set

Hosp. San Pedro de Alcantara, Cáceres, Not set

Hosp. de Jerez de La Frontera, Jerez de la Frontera, Not set

Inst. Cat. Doncologia-H Duran I Reynals, L Hospitalet De Llobregat, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp Virgen de La Victoria, Malaga, Not set

Hosp. Univ. Son Espases, Palma de Mallorca, Not set

Hosp. Clinico Univ. de Santiago, Santiago de Compostela, Not set

Inst. Valenciano de Oncologia, Valencia, Not set

Hosp. Gral. Univ. Valencia, Valencia, Not set

Hosp. Clinico Univ. Lozano Blesa, Zaragoza, Not set

Changhua Christian Hospital, ChangHua, Not set

Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

Chi-Mei Medical Center, Liouying, Tainan City, Not set

Taipei Medical University, Taipei City, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324

Active Not Recruiting

This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

05/21/2025

Locations: Weill Cornell Medicine - Multiple Myeloma Center, New York, New York

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma

Learn More ›

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175

Active Not Recruiting

This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/21/2025

Locations: Stanford University, Palo Alto, California +3 locations

Conditions: Amyloid, AL Amyloidosis, Refractory AL Amyloidosis

Learn More ›

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667

Active Not Recruiting

This is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.

Gender:

ALL

Ages:

65 years and above

Trial Updated:

05/21/2025

Locations: H. Lee Moffitt Cancer & Research Institute, Tampa, Florida

Conditions: Multiple Myeloma

Learn More ›

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664

Recruiting

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to d... Read More

Gender:

ALL

Ages:

Between 1 year and 40 years

Trial Updated:

05/21/2025

Locations: University of California San Francisco-Benioff Children's Hospital, San Francisco, California +4 locations

Conditions: Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage

Learn More ›

Dextenza for Post-operative Treatment of Pterygium

NCT04351737

Completed

DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation Compared to Standard of Care Topical Cortico-steroid Treatment in Patients who Undergo Bilateral Pterygium Surgery

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/21/2025

Locations: Brandon Eye Associates, Brandon, Florida

Conditions: Pterygium of Both Eyes

Learn More ›

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

NCT06042725

Recruiting

This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating patients with multiple myeloma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Lenalidomide is a drug that is similar to thalidomide, and i... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/20/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Multiple Myeloma

Learn More ›

Browse by State

Dexamethasone treatment options in Alabama

Dexamethasone treatment options in Alaska

Dexamethasone treatment options in Arizona

Dexamethasone treatment options in Arkansas

Dexamethasone treatment options in California

Dexamethasone treatment options in Colorado

Dexamethasone treatment options in Connecticut

Dexamethasone treatment options in Delaware

Dexamethasone treatment options in District of Columbia

Dexamethasone treatment options in Florida

Dexamethasone treatment options in Georgia

Dexamethasone treatment options in Hawaii

Dexamethasone treatment options in Idaho

Dexamethasone treatment options in Illinois

Dexamethasone treatment options in Indiana

Dexamethasone treatment options in Iowa

Dexamethasone treatment options in Kansas

Dexamethasone treatment options in Kentucky

Dexamethasone treatment options in Louisiana

Dexamethasone treatment options in Maine

Dexamethasone treatment options in Montana

Dexamethasone treatment options in Nebraska

Dexamethasone treatment options in Nevada

Dexamethasone treatment options in New Hampshire

Dexamethasone treatment options in New Jersey

Dexamethasone treatment options in New Mexico

Dexamethasone treatment options in New York

Dexamethasone treatment options in North Carolina

Dexamethasone treatment options in North Dakota

Dexamethasone treatment options in Ohio

Dexamethasone treatment options in Oklahoma

Dexamethasone treatment options in Oregon

Dexamethasone treatment options in Maryland

Dexamethasone treatment options in Massachusetts

Dexamethasone treatment options in Michigan

Dexamethasone treatment options in Minnesota

Dexamethasone treatment options in Mississippi

Dexamethasone treatment options in Missouri

Dexamethasone treatment options in Pennsylvania

Dexamethasone treatment options in Rhode Island

Dexamethasone treatment options in South Carolina

Dexamethasone treatment options in South Dakota

Dexamethasone treatment options in Tennessee

Dexamethasone treatment options in Texas

Dexamethasone treatment options in Utah

Dexamethasone treatment options in Vermont

Dexamethasone treatment options in Virginia

Dexamethasone treatment options in Washington

Dexamethasone treatment options in West Virginia

Dexamethasone treatment options in Wisconsin

Dexamethasone treatment options in Wyoming